Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском: 2025

Этот документ обновляет предыдущие консенсусы Российского медицинского общества по артериальной гипертонии и предоставляет сжатый обзор имеющейся информации, а также новых данных, подтверждающих важность контроля мочевой кислоты, как фактора риска сердечно-сосудистых осложнений. Цель данного документа заключается в упрощении принятия решения в оптимальных подходах к лечению пациентов с гиперурикемией. Особое внимание уделено проблеме стандартизации критериев гиперурикемии, определению уровней мочевой кислоты, ассоциированных с риском различных сердечно-сосудистых заболеваний, а также особенностям ведения пациентов с гиперурикемией и хронической болезнью почек. Настоящий консенсус регламентирует назначение уратснижающей терапии в зависимости от уровня мочевой кислоты и степени сердечно-сосудистого риска. Аллопуринол остается препаратом первой линии уратснижающей терапии у пациентов с гиперурикемией и высоким сердечно-сосудистым риском.

1. Чазова И.Е., Жернакова Ю.В., Кисляк О.А. и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском. Системные гипертензии. 2019;16(4):8-21. https://doi.org/ 10.26442/2075082X.2019.4.190686

2. Чазова И.Е., Жернакова Ю.В., Кисляк О.А. и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском: 2022. Системные гипертензии. 2022;19(1):5-22. https://doi.org/10.38109/2075-082X-2022-1-5-22

3. Bannasch D., Safra N., Young A., et al. Mutations in the SLC2A9 gene cause hyperuricosuria and hyperuricemia in the dog. PLoS Genet. 2008;4(11):e1000246. indexed in Pubmed: 18989453. https://doi.org/10.1371/journal.pgen.1000246

4. Bobulescu I.A., Moe O.W. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012;19(6):358-371. indexed in Pubmed: 23089270. https://doi.org/10.1053/j. ackd.2012.07.009

5. Nigam SK, Bush KT, Martovetsky G, et al. The organic anion transporter (OAT) family: a systems biology perspective. Physiol Rev. 2015;95(1):83-123. indexed in Pubmed: 25540139. https://doi.org/10.1152/physrev.00025.2013

6. Zhu Zhu Y., Pandya B.J., Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136-3141. indexed in Pubmed: 21800283. https://doi.org/10.1002/art.30520

7. Chen-Xu M., Yokose C., Rai S.K., et al. Contemporary prevalence of gout and hyperuricemia in the united states and decadal trends: the national health and nutrition examination survey, 2007-2016. Arthritis Rheumatol. 2019; 71(6): 991–999. https://doi.org/10.1002/art.40807, indexed in Pubmed: 30618180.

8. Centola M., Maloberti A., Castini D., et al. Impact of admission serum acid uric levels on in-hospital outcomes in patients with acute coronary syndrome. Eur J Intern Med. 2020;82:62-67. indexed in Pubmed: 32709548. https://doi.org/10.1016/j.ejim.2020.07.013

9. Maloberti A., Bossi I., Tassistro E., et al. Uric acid in chronic coronary syndromes: Relationship with coronary artery disease severity and left ventricular diastolic parameter. Nutr Metab Cardiovasc Dis. 2021;31(5):1501-1508. indexed in Pubmed: 33810962. https://doi.org/10.1016/j.numecd.2021.01.023

10. Maloberti A., Qualliu E., Occhi L., et al. Hyperuricemia prevalence in healthy subjects and its relationship with cardiovascular target organ damage. Nutr Metab Cardiovasc Dis. 2021;31(1):178-185. indexed in Pubmed: 32994122. https://doi.org/10.1016/j.numecd.2020.08.015

11. Piao W., Zhao L., Yang Y., et al. The prevalence of hyperuricemia and its correlates among adults in China: results from CNHS 2015–2017. Nutrients. 2022;14(19). indexed in Pubmed: 36235748. https://doi.org/10.3390/nu14194095

12. Шальнова С.А., Деев А.Д., Артамонова Г.В. и др. Гиперурикемия и ее корреляты в Российской популяции (результаты эпидемиологического исследования ЭССЕ-РФ). Рациональная Фармакотерапия в Кардиологии. 2014;10(2):153-159. https://doi.org/10.20996/1819-6446-2014-10-2-153-159

13. Шальнова С.А., Имаева А.Э., Куценко В.А. и др. Гиперурикемия и артериальная гипертония у лиц трудоспособного возраста: результаты популяционного исследования. Кардиоваскулярная терапия и профилактика. 2023;22(9S):3783. https://doi.org/10.15829/1728-8800-2023-3783

14. Kuwabara M., Hisatome I., Ae R., et al. Hyperuricemia, A new cardiovascular risk. Nutr Metab Cardiovasc Dis. 2025;35(3):103796. https://doi.org/10.1016/j.numecd.2024.103796

15. Niskanen L.K., Laaksonen D.E., Nyyssönen K., et al. Uric acid level as a risk factor for cardiovascular and allcause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164(14):1546- 1551. indexed in Pubmed: 15277287. https://doi.org/10.1001/archinte.164.14.1546

16. Desideri G., Virdis A., Casiglia E., et al. Exploration into uric and cardiovascular disease: uric acid right for heArt health (URRAH) project, a study protocol for a retrospective observational study. High Blood Press Cardiovasc Prev. 2018;25(2):197-202. indexed in Pubmed:29427170. https://doi.org/10.1007/s40292-018-0250-7

17. Virdis A., Masi S., Casiglia E., et al. Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years. Hypertension. 2020;75(2):302-308, indexed in Pubmed: 31813345. https://doi.org/10.1161/HYPERTENSIONAHA.119.13643

18. Muiesan M.L., Salvetti M., Virdis A., et al. Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. J Hypertens. 2021;39(1):62-69. indexed in Pubmed: 32694342. https://doi.org/10.1097/HJH.0000000000002589

19. Casiglia E., Tikhonoff V., Virdis A., et al. Serum uric acid and fatal myocardial infarction: The URRAH (Uric Acid Right for Heart Health) study. J Hypertens. 2020;38(3):412-419. indexed in Pubmed: 31644519. https://doi.org/10.1097/hjh.0000000000002287

20. Tikhonoff V., Casiglia E., Spinella P., et al. Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. J Hum Hypertens. 2022;36(11):976-982. indexed in Pubmed: 34588603. https://doi.org/10.1038/s41371-021-00613-5

21. Lurbe E., Torro M.I., Alvarez-Pitti J. et al. Uric acid is linked to cardiometabolic risk factors in overweight and obese youths. J Hypertens 2018;36(9):1840-6. indexed in PubMed: 29916994. https://doi.org/10.1097/HJH.0000000000001814

22. Xu X., Hu J., Song N., et al. Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis. BMC Nephrol. 2017 Jan 17;18(1):27. https://doi.org/10.1186/s12882-016-0433-1

23. Juraschek S.P., Kovell L.C., Miller E.R. et al. Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010. Semin Arthritis Rheum 2013;42(6):551-61. indexed in PubMed: 23312548. https://doi.org/10.1016/j.semarthrit.2012.09.009

24. Jing J., Kielstein J.T., Schultheiss U.T. et al. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study. Nephrol Dial Transplant 2015;30(4):613-621. indexed in PubMed: 25395390. https://doi.org/10.1093/ndt/gfu352

25. Johnson R.J., Nakagawa T., Jalal D. et al. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 2013; 28(9):2221-8. indexed in PubMed: 23543594. https://doi.org/10.1093/ndt/gft029

26. Миронова О.Ю. Гиперурикемия и поражение почек у пациентов с сердечно-сосудистыми заболеваниями. Терапевтический архив. 2022;94(12):1426-1430. https://doi.org/10.26442/00403660.2022.1 2.201999

27. Nashar K., Fried L.F. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? Adv Chronic Kidney Dis 2012;19:386-391 https://doi.org/10.1053/j.ackd.2012.05.004

28. Feig D.I., Madero M., Jalal D.I., et al. Uric acid and the origins of hypertension. J Pediatr 2013; 162:896-902. https://doi.org/10.1016/j.jpeds.2012.12.078

29. Borghi C., Rosei E.A., Bardin T. et al. Serum uric acid and the risk of cardiovascular and renal disease.J Hypertens 2015;33(9):1729-41. indexed in PubMed: 26136207. https://doi.org/10.1097/ HJH.0000000000000701

30. Hsu C.Y., Iribarren C., McCulloch C.E. et al. Risk factors for end-stage renal disease: 25-year followup.Arch Intern Med 2009; 169(4):342-50. indexed in PubMed: 19237717. https://doi.org/10.1001/ archinternmed.2008.605

31. Villegas R., Xiang Y.B., Elasy T., et al. Purine-rich foods, protein intake, and the prevalence of hyperuricemia: the Shanghai Men’s Health Study. Nutr Metab Cardiovasc Dis. 2012;22(5):409-416. indexed in Pubmed: 21277179. https://doi.org/10.1016/j.numecd.2010.07.012

32. Исайкина М.А., Исайкина О.Ю., Трушина О.Ю. Метаболически ассоциированная жировая болезнь печени. Чем опасна «безопасная» болезнь? Патогенез сердечно-сосудистых осложнений. Лечащий Врач. 2025;2(28):13-20. https://doi.org/10.51793/OS.2025.28.2.002

33. Sanchez-Lozada L.G., Andres-Hernando A., Garcia-Arroyo F.E., et al. Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats. J Biol Chem. 2019;294(11):4272-4281. indexed in Pubmed: 30651350. https://doi.org/10.1074/jbc. RA118.006158

34. Choi Y.J., Shin H.S., Choi H.S., et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress andSREBP-1c activation in hepatocytes. Lab Invest. 2014;94(10):1114-1125. indexed in Pubmed: 25111690. https://doi.org/10.1038/labinvest.2014.98

35. Jang T.Y., Yeh M.L., Huang C.I., et al. Association of hyperuricemiawith disease severity in chronic hepatitis C patients. PLoS One.2018;13(11):e0207043. indexed in Pubmed: 30395654. https://doi.org/10.1371/journal.pone.0207043

36. Petta S, Macaluso FS, Camm. C, et al. Hyperuricaemia: anothermetabolic feature affecting the severity of chronic hepatitis because of HCV infection. Liver Int. 2012;32(9):1443-1450. indexed in Pubmed: 22764879 . https://doi.org/10.1111/j.1478-3231.2012.02842.x

37. Jang T.Y., Huang C.I., Yeh M.L., et al. Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. J Gastroenterol Hepatol. 2020;35(3):473-481. indexed in Pubmed: 31414504. https://doi.org/10.1111/jgh.14835

38. Yen P-C., Chou Y-T., Li C-H., Sun Z-J., Wu C-H., Chang Y-F., Lu F-H., Yang Y-C., Chang C-J., Wu J-S. Hyperuricemia Is Associated with Significant Liver Fibrosis in Subjects with Nonalcoholic Fatty Liver Disease, but Not in Subjects without It. Journal of Clinical Medicine. 2022;11(5):1445. https://doi.org/10.3390/jcm11051445

39. Yang X., Tian X., Chen S., et al. Early onset of hyperuricemia is associated with the risk of nonalcoholic fatty liver disease across life course. Nutr Metab Cardiovasc Dis 2024;34:2740-2748. https://doi.org/10.1016/j.numecd.2024.07.022

40. Yu C., Ding C., Yu C. et al. Decoding the fatty liver-hyperuricemia link in the obese and nonobese hypertensive patients: insights from a cohort study. Sci Rep. 2024 Nov 27;14(1):29525. https://doi.org/10.1038/s41598-024-80895-0

41. Williams B., Mancia G., Spiering W., et al. [2018 ESC/ESH Guidelines for the management of arterial hypertension]. Kardiol Pol. 2019;77(2):71-159. indexed in Pubmed:30816983. https://doi.org/10.5603/KP.2019.0018

42. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии 2019;16(1):6-31 https://doi.org/10.26442/2075082X.2019.1.190179

43. Muszyński P., Dąbrowski E.J., Pasławska M., et al. Hyperuricemia as a risk factor in hypertension among patients with very high cardiovascular risk. Healthcare (Basel). 2023 Sep 3;11(17):2460. indexed in Pubmed: 37685494. https://doi.org/10.3390/healthcare11172460

44. Saito Y., Tanaka A., Node K., et al. Uric acid and cardiovascular disease: a clinical review. J Cardiol. 2021;78(1):51-57. indexed in Pubmed: 33388217. https://doi.org/10.1016/j.jjcc.2020.12.013

45. Borghi C., Agabiti-Rosei E., Johnson R.J., et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1-11. indexed in Pubmed: 32739239. https://doi.org/10.1016/j.ejim.2020.07.006

46. Moshkovits Y., Tiosano S., Kaplan A., et al. Serum uric acid significantly improves the accuracy of cardiovascular risk score models. Eur J Prev Cardiol. 2023;30(7):524-532. indexed in Pubmed: 36378558. https://doi.org/10.1093/eurjpc/zwac275

47. Obrycki Ł., Feber J., Brzezińska G., et al. Evolution of isolated systolic hypertension with normal central blood pressure in adolescents-prospective study. Pediatr Nephrol. 2021;36(2):361-371. indexed in Pubmed:32880746. https://doi.org/10.1007/s00467-020-04731-z

48. Wang A., Tian X., Wu S., et al. Metabolic factors mediate the association between serum uric acid to serum creatinine ratio and cardiovascular disease. J Am Heart Assoc. 2021;10(23):e023054. indexed in Pubmed: 34779219. https://doi.org/10.1161/JAHA.121.023054

49. Maloberti A., Biolcati M., Ruzzenenti G., et al. The role of uric acid in acute and chronic coronary syndromes. J Clin Med. 2021;10(20). indexed in Pubmed:34682873. https://doi.org/10.3390/jcm10204750

50. Wheeler J.G., Juzwishin K.D., Eiriksdottir G., et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med. 2005;2(3):e76. https://doi.org/10.1371/journal.pmed.0020076

51. Mackenzie I.S., Ford I., Walker A., et al. Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study. BMJ Open. 2016;6(9):e013774. indexed in Pubmed: 27609859. https://doi.org/10.1136/bmjopen-2016-013774

52. Mackenzie I., Hawkey C., Ford I., et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-end-point trial. Lancet. 2022;400(10359):1195-1205. indexed in Pubmed: 36216006. https://doi.org/10.1016/s0140- 6736(22)01657-9

53. Akashi N., Kuwabara M., Matoba T., et al. Hyperuricemia predicts increased cardiovascular events in patients with chronic coronary syndrome after percutaneous coronary intervention: A nationwide cohort study from Japan. Front Cardiovasc Med. 2022;9:1062894. indexed in Pubmed: 36704454. https://doi.org/10.3389/fcvm.2022.1062894

54. Bombelli M., Ronchi I., Volpe M., et al. Prognostic value of serum uric acid: new-onset in and out-ofoffice hypertension and long-term mortality. J Hypertens. 2014;32(6):1237-1244. indexed in Pubmed: 24675682. https://doi.org/10.1097/HJH.0000000000000161

55. Блинова Н.В., Чазова И.Е. Гиперурикемия и артериальная гипертония: взаимосвязи и риски. Лечебное дело. 2021;1:45-51. EDN OAYZDW. https://doi.org/10.24412/2071-5315-2021-12290

56. Cheng Y.B., Li Y. Hyperuricemia: Does It Matter for the Progression From Prehypertension to Hypertension? Hypertension. 2018;71(1):66-67. indexed in Pubmed: 29203631. https://doi.org/10.1161/HYPERTENSIONAHA.117.10443

57. Grayson P.C., Kim S.Y., LaValley M., et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102-110. indexed in Pubmed: 20824805. https://doi.org/10.1002/acr.20344

58. Fotherby M.D., Potter J.F. Metabolic and orthostatic blood pressure responses to a low-sodium diet in elderly hypertensives. J Hum Hypertens 1997;11(6):361-366. indexed in PubMed: 9249230. https://doi.org/10.1038/sj.jhh.1000436

59. Singh J.A., Reddy S.G., Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol 2011;23(2):192-202. indexed in PubMed: 21285714. https://doi.org/10.1097/BOR.0b013e3283438e13

60. Jacob R.A., Spinozzi G.M., Simon V.A. et al. Consumption of cherries lowers plasma urate in healthy women. J Nutr 2003;133(6):1826-9. indexed in PubMed: 12771324. https://doi.org/10.1093/jn/133.6.1826

61. Schlesinger N. Dietary factors and hyperuricaemia. Curr Pharm Des 2005;11(32):4133-4138. indexed in PubMed: 16375734. https://doi.org/10.2174/138161205774913273

62. Richette P., Poitou C., Manivet P. et al. Weight Loss, Xanthine Oxidase, and Serum Urate Levels: A Prospective Longitudinal Study of Obese Patients. Arthritis Care Res (Hoboken) 2016;68(7):1036-1042. indexed in PubMed: 26844534. https://doi.org/10.1002/acr.22798

63. Chen J.H., Wen C.P., Wu S.B. et al. Attenuating the mortality risk of high serum uric acid: the role of physical activity underused. Ann Rheum Dis 2015;74(11):2034-2042. indexed in PubMed: 25053714. https://doi.org/10.1136/annrheumdis-2014-205312

64. Стародубова А.В., Чазова И.Е., Тутельян В.А., и соавт. Евразийские клинические рекомендации по питанию при сердечно-сосудистых заболеваниях (2024). Евразийский кардиологический журнал. 25 ноября 2024;(4):6-66. https://doi.org/10.38109/2225-1685-2024-4-6-66

65. Li Q., Li X., Wang J., et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2019;9(8):e026677. https://doi.org/10.1136/bmjopen-2018-026677

66. Goicoechea M., García-Marina R. Hiperuricemia en pacientes con enfermedad renal crónica: ¿Cuándo y con qué tratar? Nefrología 2025;501334. (In Spanish) https://doi.org/10.1016/j.nefro.2025.501334

67. Bardin T., Richette P. FAST: new look at the febuxostat safety profile. Lancet. 2020;396(10264):1704-1705. indexed in Pubmed: 33181079. https://doi.org/10.1016/S0140-6736(20)32343-6

68. Mackenzie I.S., Ford I., Nuki G., et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, noninferiority trial. Lancet. 2020;396(10264):1745-1757. https://doi.org/10.1016/S0140-6736(20)32234-0

69. White W.B., Saag K.G., Becker M.A., et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200-1210. indexed in Pubmed: 29527974. https://doi. org/10.1056/NEJMoa1710895

70. Keenan R.T., Pillinger M.H. Febuxostat: A new agent for lowering serum urate. Drugs of Today. 2009;45(4):247. https://doi.org/10.1358/dot.2009.045.004.1354217

71. Миронова О.Ю., Фомин В.В. Гиперурикемия у пациентов со стабильной ишемической болезнью сердца и артериальной гипертензией и чрескожные коронарные вмешательства. Consilium Medicum. 2020;22(12):20-22. https://doi.org/10.26442/20751753.2020.12.200555

72. Kielstein J.T., Pontremoli R., Burnier M. Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection. Curr Hypertens Rep 2020;22:102. https://doi.org/10.1007/s11906-020-01116-3

73. Ghossan R., Aitisha Tabesh O., Fayad F., Richette P., Bardin T. Cardiovascular Safety of Febuxostat in Patients With Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials. J Clin Rheumatol. 2024;30(2):e46-e53. https://doi.org/10.1097/RHU.0000000000002045

74. Чазова И.Е., Чихладзе Н.М., Блинова Н.В. и соавт. Клинические рекомендации Российского медицинского общества по артериальной гипертонии (РМОАГ) и Евразийской Ассоциации Кардиологов (ЕАК) по диагностике и лечению артериальной гипертонии (2024). Системные гипертензии. 25 декабря 2024;21(4):5-109. https://doi.org/10.38109/2075-082X-2024-4-5-109

75. Mancia G., Kreutz R., Brunström M., et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2024 Jan 1;42(1):194. https://doi.org/10.1097/HJH.0000000000003621

76. Borghi C., Domienik-Karłowicz J., Tykarski A., et al. Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update. Cardiol J. 2024;31(1):1-14. https://doi.org/10.5603/cj.98254

77. Matsumura K, Arima H, Tominaga M, et al. Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study. Clin Exp Hypertens. 2015;37(3):192-196. indexed in Pubmed: 25051056. https://doi.org/10.3109/10641963.2014.933968

78. Stamp L.K., et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012 Aug;64(8):2529-36. https://doi.org/10.1002/art.34488

79. Richette P., Doherty M., Pascual E., et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. indexed in Pubmed: 27457514. https://doi. org/10.1136/annrheumdis-2016-209707

80. Hande K.R., Noone R.M., Stone W.J. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76(1):47-56. indexed in Pubmed: 6691361. https://doi.org/10.1016/0002-9343(84)90743-5

81. Hershfield M.S., Callaghan J.T., Tassaneeyakul W., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013;93(2):153-158. indexed in Pubmed: 23232549. https://doi.org/10.1038/clpt.2012.209

82. Deeks E.D. Lesinurad: a review in hyperuricaemia of gout. Drugs Aging. 2017;34(5):401-410. indexed in Pubmed: 28425024. https://doi.org/10.1007/s40266-017-0461-y

83. Pérez-Ruiz F., Jansen T., Tausche A.K., et al. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout. Drugs Context. 2019;8:212581. indexed in Pubmed: 31191704. https://doi.org/10.7573/dic.212581

84. Saag K.G., Fitz-Patrick D., Kopicko J., et al. Lesinurad combined with allopurinol: a randomized, doubleblind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a us-based study). Arthritis Rheumatol. 2017;69(1):203-212. indexed in Pubmed: 27564409. https://doi.org/10.1002/art.39840

85. Kochanowska A., Rusztyn P., Szczerkowska K., et al. Sodium-Glucose cotransporter 2 inhibitors to decrease the uric acid concentration-a novel mechanism of action. J Cardiovasc Dev Dis. 2023;10(7):268. indexed in Pubmed: 37504524. https://doi.org/10.3390/jcdd10070268

86. Yip A.S.Y., Leong S., Teo Y.H., et al. Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials. Ther Adv Chronic Dis. 2022;13:20406223221083509. indexed in Pubmed: 35342538. https://doi.org/10.1177/20406223221083509

87. De Becker B, Borghi C, Burnier M, van de Borne P. Uric acid and hypertension: a focused review and practical recommendations. J Hypertens. 2019 May;37(5):878-883. https://doi.org/10.1097/HJH.0000000000001980